← All trials
NCT06452654
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 8, 2024
- Primary completion
- Oct 31, 2027
- Completion date
- Oct 31, 2027
- First posted
- Jun 11, 2024
- Last posted
- Aug 1, 2024
- Enrollment
- 2252
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Technical University of MunichLead sponsor
- University of CambridgeCollaborator
- Lund UniversityCollaborator
- Technical University of DresdenCollaborator
- Gottfried Wilhelm Leibniz Universität HannoverCollaborator
- Katholieke Universiteit LeuvenCollaborator
- Helmholtz Centre for Infection ResearchCollaborator
- Newcastle UniversityCollaborator
- University of BirminghamCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.